Slide 1: Cover letter to stock exchanges: Investor Presentation
Date: June 23, 2026 To, National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, Listing Department Bandra Kurla Complex, Floor 25, P J Towers, Bandra (East), Mumbai – 400051 Dalal Street, Mumbai – 400001 Maharashtra, India. Maharashtra, India. Symbol: FABTECH Scrip Code: 5
Slide 2: India's Global Life Sciences Infrastructure Platform
INVESTOR PRESENTATION · FY26 India’s Global Life Sciences Infrastructure Platform Engineering medicinal sovereignty across the pharma- emerging geographies. BSE Main Board · “FABTECH” 62+ countries 500+ projects delivered
Slide 3: We build the factories that make medicines
WHAT FABTECH DOES We build the factories that make Process medicines. Manufacturing & process equipment integrated into the production line. Every vaccine, IV solution and tablet is made inside a certified, sterile facility. Fabtech is the end-to-end Air turnkey provider that designs, engineers, bui
Slide 4: One integrated group platform
THE GROUP ECOSYSTEM One integrated group platform. Three decades of engineering, presence across 62+ countries, and 78% of revenue from MENA, GCC & ECO Zone markets — an asset-light model that scales through in-house arms and strategic partners. UAE 100% 100% 49% ~16% 33.33%
Slide 5: Six capability domains, built in Fabtech group
MANUFACTURING CAPABILITIES Six capability domains, built in Fabtech group. Every solution is custom-designed and built at our own facilities — covering OSD, sterile liquids, vaccines, oncology, hormones & biosimilars. Cleanroom Sterilisation Containment Modular & bio-cleanrooms, HVAC Air & contained
Slide 6: Turnkey engineering across the full value chain
SERVICE OFFERING Turnkey engineering across the full value chain. Design Engineering Procurement Construction Management + Project Controls Advisory & Consulting Vendor Selection New Plant / Plant Technology Tie-up / Project Management Upgradation Transfer Design & Conception Equipment & Systems Aud
Slide 7: A resilient year, and a wider runway ahead
THE FY26 STORY A resilient year, and a wider runway ahead. Operational continuity Growth visibility Regional expansion War Impact Project execution momentum held A ₹900+ Cr order book underpins UAE & Saudi localisation, JVs and a Near-term conflict disrupts delivery strong through freight volatility
Slide 8: Scaling, with discipline
FY26 RESULTS · YEAR ENDED 31 MARCH 2026 Scaling, with discipline. Standalone results ₹ in Crore | vs FY25 Revenue from Operations Operational Profit Reported Net Profit (PAT) Order Book ₹410.77 ₹36.60 ₹38.36 ₹900+ ↑ 25.7% YoY ↑ 17.0% YoY Normalised exceptionals Healthy visibility vs ₹326.67 in FY25
Slide 9: Resilient delivery, an expanding platform
STRATEGIC UPDATE Resilient delivery, an expanding platform. Strong order book position Resilient performance amid volatility Consolidated order book of ₹900+ Cr as of 31 March 2026 — providing Navigated logistics disruptions, freight challenges and input-cost pressures strong revenue visibility and
Slide 10: Consolidated order book as of Mar 2026
Consolidated order book · as of 31 Mar 2026 ORDER BOOK & PIPELINE ₹900+ Cr Visibility you can underwrite. Confirmed orders ready for execution. A confirmed book funds execution for the coming periods, while a step-change in conversion turns Conversion target a deep enquiry pipeline into structural g
Slide 11: New mandates across high-growth markets
STRATEGIC PROJECT WINS New mandates across high-growth markets. Marquee wins expanding our sector and geographic reach — anchoring the ₹900+ Cr order book. WEST AFRICA SAUDI ARABIA NORTH AFRICA Oral Solid Dosage Facility Animal Vaccine Project Next-Gen Veterinary Facility USD 7.05M USD 7.8M ₹49–52 C
Slide 12: Firsts and largests that competitors can't easily follow
BENCHMARK PROJECTS Firsts and largests that competitors can’t easily follow. Each landmark project builds regulatory credibility — creating reference moats, entry barriers and a repeat pipeline. LARGEST FIRST UAE’S ONLY FIRST FIRST IV Solution Facility Biosimilars Facility USFDA-Approved Oncology Pr
Slide 13: Global engineering, local execution
GLOBAL PRESENCE Global engineering, local execution. India UAE Saudi Arabia Jordan 62+ countries delivered Engineering & Regional HQ & IV & oncology facilities MENA project delivery manufacturing base USFDA facility 500+ projects completed Egypt Algeria Nigeria 2000+ GCC · MENA · Africa Core growth
Slide 14: Three levers to compound from here
GROWTH STRATEGY · PLAN AHEAD Three levers to compound from here. European Acquisition Joint Ventures Working-Capital Strength Strengthening brand presence, entering Strengthening presence in KSA, East Africa Improved liquidity for smoother cycles — premium markets, expanding margins and enabling fas
Slide 15: A large, structurally-funded addressable market
MARKET OPPORTUNITY A large, structurally-funded addressable market. Fabtech’s scope covers 60%+ of project spend — Air, Water, Process, Cleanrooms and Utilities. Global TAM Fabtech SAM KSA Build-Out Africa $180B $28–30B $15B+ $60B+ Turnkey pharma & biotech Core geographies: GCC, Africa & Pharma manu
Slide 16: Local where it counts — and the advantage is ours
LOCALISATION ADVANTAGE UAE · Domestic KSA · Domestic Local where it counts — and the advantage is ours. By becoming a domestic company in the UAE and Saudi Arabia, we unlock a natural tax advantage and the full weight of being local. Natural tax advantage Local-content preference Proximity & trust D
Slide 17: Own the building, own the timeline
EXECUTION CONTROL · PEB SCOPE Own the building, own the timeline. The challenge today Our move — take the PEB scope Project duration 2–3 years By owning the pre-engineered building scope, we control the Fabtech shipment (~90%) 1–1.5 years civil works, the timeline and the deliverables of the entire
Slide 18: From 8–9% to 11–13% PAT margin
MARGIN EXPANSION ROADMAP From 8–9% to 11–13% PAT margin. Three structural levers compound straight into the bottom line. + Ticket & efficiency + 2–3% 11–13% + Tax & local 8–9% Today Localisation Alternative sourcing PEB & execution Target margin
Slide 19: We are not a quarter-to-quarter story
BUILDING LONG-TERM VALUE We are not a quarter-to-quarter story. We build multi-year, mission-critical facilities — and compound shareholder value across cycles. FY27 standalone revenue FY27 standalone PAT ₹500 Cr ₹45 Cr Current-year trajectory — ~9% PAT margin, expanding toward 11–13%.
Slide 20: Climbing the value curve to advanced-technology facilities
FTL 2030 VISION Climbing the value curve to advanced-technology facilities. Beyond conventional pharma — turnkey design-and-build for the most complex, highest-value life-sciences builds. Medical Diagnostics Vaccines Biotech Cell & Gene Therapy High-Tech Facilities How we enter these markets: Local
Slide 21: A 15-year structural opportunity
FTL 2030 VISION · THE OPPORTUNITY A 15-year structural opportunity — and the platform built to capture it. 15-year runway Scalable model Reference-led moat A structural shift toward regional medicinal In-house ecosystem that scales across Every landmark project compounds sovereignty. formats and geo
Slide 22: We enable the world to manufacture life-saving medicines
We enable the world to manufacture life-saving medicines — without having made a single pill. Thank you. BSE Main Board · “FABTECH” Life Engineering™